For U.S. Healthcare Professionals Only
For Patients Full Prescribing Information including Boxed WARNING
Please see full prescribing information including boxed WARNING.
* For measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST).
mHRPC=hormone-refractory metastatic prostate cancer; PSA=prostate-specific antigen.
1. JEVTANA® Prescribing Information. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2014.
2. de Bono JS, Oudard S, Ozguroglu M, et al; for the TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
JEVTANA® is a microtubule inhibitor
indicated in combination with prednisone
for the treatment of patients with
hormone-refractory metastatic prostate
cancer (mHRPC) previously treated with a
docetaxel-containing treatment regimen.
© 2014 sanofi-aventis U.S. LLC, A SANOFI COMPANY All rights reserved.
| Site Map | Contact Us
This site is intended for use by U.S. Healthcare Professionals only.